StockData
PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31

Phathom Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.01+0.09 (+1.30%)

Close on Oct 19, 2026

Market cap
$587.07M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 29, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026Before market open$74.30M––
Q1 FY2026
Ended Mar 31, 2026
Apr 30, 2026Before market open$58.30M$-0.37$-0.18
Q4 FY2025
Ended Dec 31, 2025
Jan 7, 2026After market close–––
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025Before market open$49.50M$-0.41$-0.15
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025Before market open$39.50M$-1.05$-0.79
Q1 FY2025
Ended Mar 31, 2025
May 1, 2025Before market open$28.50M$-1.31$-1.07
Q4 FY2024
Ended Dec 31, 2024
Mar 6, 2025Before market open$29.70M––
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024Before market open$16.40M$-1.32$-1.05
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open$7.30M$-1.56$-1.25
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024Before market open$1.90M$-1.42$-1.11
Q4 FY2023
Ended Dec 31, 2023
Mar 7, 2024Before market open$700.00K$-1.39$-0.80

Company guidance

Outlook given with results on Jul 30, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
gross marginthe remainder of 2026 and for the full year80%Maintained
gross-to-net discountthe remainder of 2026 and for the full year55% to 59%Maintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Phathom Pharmaceuticals filed with the SEC